☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
UroGen Pharma
UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
May 6, 2024
UroGen Pharma Reports P-III Trial (ATLAS) Results of UGN-102 for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 9, 2023
UroGen Pharma Reports P-III Trials (ATLAS) and (ENVISION) Results of UGN-102 as First Non-Surgical Therapy for Non-Muscle Invasive...
July 29, 2023
Load more...
Back to Home
